Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, 430022, China
NCT Number: NCT07799623
This study will compare three anesthesia medicines used to put people into a deep sleep during surgery: ciprofol, propofol, and sevoflurane. All three are commonly used for general anesthesia, but they work in different ways. Ciprofol and propofol are given through a vein. Sevoflurane is breathed in as a gas. After brain tumor surgery, some older adults may develop sudden confusion and memory problems called delirium. Researchers want to learn which of these three medicines is best at preventing delirium and protecting brain function in older adults undergoing brain tumor surgery.
About 381 participants aged 65 to 90 will take part. Participants will be randomly assigned to one of three groups. One group will receive ciprofol. Another group will receive propofol. The third group will receive sevoflurane. All participants will receive standard care during and after brain tumor removal.
The main goal is to compare how many participants develop delirium within 7 days after surgery. Researchers will also look at how long delirium lasts, how severe it is, thinking and memory skills at 7, 30, 90, and 180 days after surgery, quality of recovery, blood pressure and heart rate during surgery, and treatment safety.
Blood tests will be used to measure markers of body stress, inflammation, and nerve cell injury before surgery, 3 hours after surgery, and 1 day after surgery. Researchers will also test thinking and memory with simple questions twice a day for 7 days after surgery. Later follow-up will be done by phone at 30, 90, and 180 days after surgery.
This study is designed to explore which anesthesia medicine is safest and best at protecting the brain after surgery in older adults with brain tumors. The results may help doctors choose the best anesthesia for this group of patients in the future.
Trial opening soon.
Get Notified65 year–90 year
All sexes
Interventional
Not applicable
Wuhan, Hubei, 430022, China
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Ciprofol injectable emulsion (20 mL: 50 mg) administered intravenously for general anesthesia induction and maintenance during elective brain tumor resection. Induction: 0.3-0.4 mg/kg by slow intravenous injection over ≥30 seconds. Maintenance: continuous intravenous infusion at 0.4-2.4 mg/kg/h via infusion pump, beginning after induction and continuing until the end of surgery. Dose adjustments are made based on patient response and hemodynamic monitoring. Total duration depends on operative time.
Propofol injectable emulsion administered intravenously for general anesthesia induction and maintenance during elective brain tumor resection. Induction: 1.5-2.0 mg/kg by slow intravenous injection over ≥30 seconds. Maintenance: continuous intravenous infusion at 4-12 mg/kg/h via infusion pump, beginning after induction and continuing until the end of surgery. Dose adjustments are made based on patient response and hemodynamic monitoring. Total duration depends on operative time.
Sevoflurane inhalation solution (volatile liquid) administered via inhalation through a calibrated vaporizer for general anesthesia induction and maintenance during elective brain tumor resection. Induction: 7-8% inhaled concentration with oxygen flow 2-4 L/min until loss of consciousness. Maintenance: inhaled concentration adjusted to 1.0-3.0% and titrated to effect; concentration is gradually reduced beginning 30 minutes before the anticipated end of surgery and discontinued at the end of the procedure. Total duration depends on operative time.
Time frame: Postoperative 2 hours, 6-12 hours, and twice daily (08:00-10:00 and 18:00-20:00) from postoperative Day 1 through Day 7
Delirium is diagnosed using the Confusion Assessment Method (CAM). A positive CAM assessment requires the simultaneous presence of Feature 1 (acute onset and fluctuating course) and Feature 2 (inattention), plus either Feature 3 (disorganized thinking) or Feature 4 (altered level of consciousness). The outcome is reported as the proportion of participants with at least one positive CAM assessment during the 7-day postoperative period.
Time frame: Postoperative Day 1 through Day 7
Duration is defined as the time interval from the first positive CAM diagnosis of delirium to the first assessment showing no delirium symptoms (CAM negative) for a continuous period of at least 24 hours. Recorded in days. If delirium persists beyond 7 days, the maximum recorded duration is 7 days.
Time frame: Postoperative Day 1 through Day 7 (twice daily assessments)
The CAM-Severity scale quantifies delirium severity based on CAM features. The 4-item version ranges from 0 to 7 points; the 10-item version ranges from 0 to 19 points. Higher scores indicate more severe delirium. The mean daily score is calculated by averaging all CAM-S scores obtained during each calendar day.
Time frame: Baseline (1 day before surgery) and postoperative Day 7
The Telephone Montreal Cognitive Assessment (T-MoCA) evaluates cognitive function including attention, memory, language, and orientation. Total scores range from 0 to 22 points, with higher scores indicating better cognitive function. A score of 18 or above indicates normal cognitive function. Change from baseline is calculated as the post-treatment score minus the baseline score; a positive change indicates improvement and a negative change indicates decline.
Time frame: Baseline (1 day before surgery) and postoperative Day 30
The Telephone Montreal Cognitive Assessment (T-MoCA) evaluates cognitive function including attention, memory, language, and orientation. Total scores range from 0 to 22 points, with higher scores indicating better cognitive function. Change from baseline is calculated as the post-treatment score minus the baseline score; a positive change indicates improvement and a negative change indicates decline.
Time frame: Baseline (1 day before surgery) and postoperative Day 90
The Telephone Montreal Cognitive Assessment (T-MoCA) evaluates cognitive function including attention, memory, language, and orientation. Total scores range from 0 to 22 points, with higher scores indicating better cognitive function. Change from baseline is calculated as the post-treatment score minus the baseline score; a positive change indicates improvement and a negative change indicates decline.
Time frame: Baseline (1 day before surgery) and postoperative Day 180
The Telephone Montreal Cognitive Assessment (T-MoCA) evaluates cognitive function including attention, memory, language, and orientation. Total scores range from 0 to 22 points, with higher scores indicating better cognitive function. Change from baseline is calculated as the post-treatment score minus the baseline score; a positive change indicates improvement and a negative change indicates decline.
Time frame: Baseline (1 day before surgery) and postoperative Day 1
The 15-item Quality of Recovery scale (QoR-15) assesses physical and psychological recovery after surgery. Each item is scored from 0 (never able to achieve the state) to 10 (always able to achieve the state), with a total score range of 0 to 150. Higher scores indicate better quality of recovery. Change from baseline is calculated as the post-treatment score minus the baseline score.
Time frame: Baseline (1 day before surgery) and postoperative Day 3
The 15-item Quality of Recovery scale (QoR-15) assesses physical and psychological recovery after surgery. Each item is scored from 0 (never able to achieve the state) to 10 (always able to achieve the state), with a total score range of 0 to 150. Higher scores indicate better quality of recovery. Change from baseline is calculated as the post-treatment score minus the baseline score.
Time frame: From PACU admission to PACU discharge, with assessments at 2, 30, 60, 90, 120, 150, and 180 minutes after extubation
The Richmond Agitation-Sedation Scale (RASS) assesses the level of consciousness and agitation in the post-anesthesia care unit (PACU). Scores range from -5 (unarousable) to +4 (combative), with 0 indicating alert and calm. Higher positive scores indicate greater agitation; more negative scores indicate deeper sedation. The maximum RASS score is defined as the highest score observed across all serial assessments from admission to the PACU until discharge. A higher maximum score indicates more severe postoperative agitation.
Time frame: During anesthesia induction (measured in minutes)
Time from the start of anesthetic drug administration to loss of eyelash reflex and unresponsiveness to verbal command, indicating successful anesthesia induction.
Time frame: From end of surgery to emergence in the PACU (measured in minutes)
Time from cessation of all anesthetic agents to eye opening in response to verbal command or spontaneous movement, indicating recovery of consciousness.
Time frame: From end of surgery to extubation in the PACU (measured in minutes)
Time from cessation of all anesthetic agents to removal of the endotracheal tube after the return of adequate spontaneous breathing, airway reflexes, and consciousness.
Time frame: From PACU admission to PACU discharge (measured in minutes)
Time from admission to the post-anesthesia care unit (PACU) to meeting discharge criteria (Steward recovery score ≥ 4) and transfer to the ward.
Time frame: Baseline (pre-induction) and intraoperative time points: 1 minute after induction, at intubation, at dural incision, and at end of surgery
Mean arterial pressure (MAP) is measured continuously via invasive arterial monitoring. Baseline MAP is obtained before anesthesia induction with the participant at rest. Change from baseline is calculated as the value at each intraoperative time point minus the baseline value. Negative values indicate a decrease from baseline; positive values indicate an increase.
Time frame: Baseline (pre-induction) and intraoperative time points: 1 minute after induction, at intubation, at dural incision, and at end of surgery
Heart rate (HR) is measured continuously via electrocardiogram monitoring. Baseline HR is obtained before anesthesia induction with the participant at rest. Change from baseline is calculated as the value at each intraoperative time point minus the baseline value. Negative values indicate a decrease from baseline; positive values indicate an increase.
Time frame: Baseline (1 day before surgery), 3 hours after surgery, and 1 day after surgery
Serum SOD is measured by standardized laboratory assay as a marker of oxidative stress. Change from baseline is calculated as the postoperative concentration minus the preoperative concentration. Higher levels indicate greater antioxidant capacity.
Time frame: Baseline (1 day before surgery), 3 hours after surgery, and 1 day after surgery
Serum IL-6 is measured by standardized laboratory assay as a marker of inflammation. Change from baseline is calculated as the postoperative concentration minus the preoperative concentration. Higher levels indicate greater inflammatory response.
Time frame: Baseline (1 day before surgery), 3 hours after surgery, and 1 day after surgery
Serum S100β is measured by standardized laboratory assay as a marker of glial cell injury and blood-brain barrier disruption. Change from baseline is calculated as the postoperative concentration minus the preoperative concentration. Higher levels indicate greater central nervous system injury.
Contact information is provided by the study sponsor or research team.
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05776706
Aneurysm, Arteriovenous Malformations
Seoul, South Korea
View Trial DetailsNCT05538130
Advanced or Metastatic Solid Tumors, Brain Diseases
Birmingham, Alabama, United States
View Trial DetailsNCT04940507
Brain Diseases, Brain Neoplasms
Toronto, Ontario, Canada
View Trial DetailsNCT07716579
Brain Diseases, Brain Neoplasms
Ljubljana, Slovenia
View Trial Details